The immunocompromised host: Immune alterations in splenectomized patients and clinical implication

Current Pharmaceutical Design

Volumn 9, Issue 24, 2003, Pages 1918-1923

  Jirillo, E ^a   Mastronardi, M L ^a   Altamura, M ^a   Munno, I ^a   Miniello, S ^b   Urgesi, G ^a   Amati, L ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Sci Inst Gastrointestinal Diseases   (Italy)

Author keywords

Lymphocytes; Macrophages; Spleen; T helper cells; Vaccines

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; PENICILLIN G; PNEUMOCOCCUS VACCINE;

APOPTOSIS; BACTERIAL INFECTION; DISEASE SEVERITY; GRAM NEGATIVE BACTERIUM; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOPATHOLOGY; MICROORGANISM; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SERUM; SPLEEN; SPLENECTOMY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-INFECTIVE AGENTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCOCCAL VACCINES; SPLEEN; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE;

EID: 0041677656     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454306     Document Type: Review

References (60)

1. Von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020.
2. Van Rooijen N. Antigen processing and presentation in vivo: the microenvironment as a crucial factor. Immunol Today 1990; 11: 436.
3. Van der Ertwegh AJM, Laman JD, Noelle RJ, Boersma WJ, Claassen E. In vivo T-B cell interactions and cytokine-production in the spleen. Seminars Immunol 1994; 6: 327.
4. Williams IR, Kupper TS. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 1996; 58: 1485.
5. Netea MG, Van Deuren M, Kullberg BJ, Cavaillon JM, Van der Meer JWM. Does the shape of lipid A determine the interaction of LPS with Toll-Like receptors?. Trends Immunol 2002; 23: 135.
6. Timens W. The human spleen and the immune system: not just another lymphoid organ. Res Immunol 1991; 142: 316.
7. Van den Dobbelsteen GPJM, Brunekreef K, Kroes H, van Rooijen N, van Rees EP. Enhanced triggering of mucosal immune responses by reducing splenic phagocytic functions. Eur J Immunol 1993; 23: 1448.
8. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301.
9. Mondino AA, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 1996; 93: 2245.
10. Shaw S, Ebnet K, Kaldjian P, Anderson AO. Orchestrated information transfer underlying leukocyte endothelial interactions. Annu Rev Immunol 1996; 14: 155.
11. Banchereau J, Rousset F. Adv Immunol 1996; 14: 125.
12. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994; 367: 425.
13. Foy TM, Aruffo A, Bajorath J, Bualman JE, Noells RJ. Annu Rev Immunol 1996; 14: 591.
14. Kelsoe G. In situ studies of the germinal center reaction. Adv Immunol 1995; 60: 267.
15. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993; 11: 331.
16. Stavnezer J. Antibody class switching. Adv Immunol 1996; 61: 79.
17. Sprent JT. Cell 1994; 76: 315.
18. Hebert JC, O'Reilly M, Yuenger K, Shatney L, Yoder DW, Barry B. Augmentation of alveolar macrophage phagocytic activity by granulocyte colony stimulating factor and interleukin-1: influence of splenectomy. J Trauma 1994; 37: 909.
19. O'Neal BJ, Mc Donald JC. The risk of sepsis in the asplenic adult. Ann Surg 1981; 194: 775.
20. Bridgen ML. Overwhelming postsplenectomy infection still a problem. West J Med 1992; 157: 440.
21. Norris RP, Vergis EN, Yu UL. Overwhelming postsplenectomy infection: a critical review of etiologic pathogens and management. Infect Med 1996; 13: 779.
22. Altamura M, Caradonna L, Amati L, Pellegrino NM, Urgesi G, Miniello S. Slenectomy and sepsis: the role of the spleen in the immune-mediated bacterial clearance. Immunophar-macol Immunotoxicol 2001; 23: 153.
23. Miniello S, Jirillo E, Urgesi G, D'Abbicco D, Altamura M, Tomasicchio N, et al. Th1-Th2 cytokine correlates (IFN-gamma and IL-4) in splenectomized patients. Chir Ital 1999; 51: 215.
24. Miniello S, Jirillo E, Urgesi G, D'Abbicco D, Tomasicchio N, Bonomo GM. Cell-mediated immunity and delayed hypersensitivity study in splenectomy patients: a compara-tive evaluation between IFN-gamma and skin tests. Chir Ital 1999; 51: 289.
25. Erb KJ, Ruger B, Von Brevern M, Ryffel B, Schimpl A, Rivett K. Costitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997; 185: 329.
26. Kühn R, Rajewsky K, Müller W. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254: 707.
27. Mori M, Morris SC, Orekhova T, Marinaro M, Giannini E, Finkelman FD. IL-4 promotes the migration of circulating B cells to the spleen and increases splenic B cell survival. J Immunol 2000; 164: 5704.
28. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, et al. CD14 is a pattern recognition receptor. Immunity 1994: 1; 509.
29. Espevik T, Otterlei M, Skjak-Braek G, Ryan L, Wright SD, Sundan A. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur J Immunol 1993; 23: 255.
30. Medvedev AE, Flo T, Ingalls RR, Golenbock DT, Teti G, Vogel SN, et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappa B activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. Immunol 1998; 160: 4535.
31. Freudenberg N, Freudenberg MA, Bandara K, Galanos C. Distribution and localization of endotoxin in the reticulo-endothelial system (RES) and in the main vessels of the rat during shock. Pathol Res Pract 1985; 179: 517.
32. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, et al. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002; 8: 319.
33. Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, Manghisi OG, et al. Biological clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Design 2002; 8: 995.
34. Brade H, Opal SM, Vogel SN, Morrison DC, (EDITORS) Endotoxin in health and disease. New York Marcel Dekker, 1999.
35. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. Exp Med 1994; 179: 269.
36. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 1994; 6: 125.
37. Yang RB, Mark MR, Gurney AL, Godowski PJ. Signaling events induced by lipopolysaccharide-activated toll-like receptor 2. J Immunol 1999; 163: 639.
38. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15: 95.
39. Andersson UG, Björk L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211.
40. Reimund JM, Dumont S, Muller CD, Kenney S, Kedinger M, Baumann R, et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997; 40: 475.
41. Famularo G, De Simone C, Arrigoni-Martelli E, Jirillo E. Carnitine and septic shock: a review. J Endotoxin Res 1995; 2: 141.
42. Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029.
43. Stack WA, Mann SD, Roy AJ, Health P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521.
44. Dinarello CA. Blocking interleukin-1 in sepsis. J Endotoxin Res 1995; 2: 157.
45. Hirschmann JV. Use of the pneumococcal polysaccharide vaccine is unwarranted in the U.S. ASM News 2000; 66: 326.
46. Dennehy PH. Active immunization in the United States: development over the past decade. Clin Microbiol Rev 2001; 14: 872.
47. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826.
48. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999; 18: 543.
49. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1: 1.
50. Snapper CM, Shen Y, Khan AQ, Colino J, Zelazowski P, Mond JJ, et al. Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae. Trends Immunol 2001; 22: 308.
51. Haraguchi S, Day NK, Nelson RP, Jr. Emmanuel P, Duplantier JE, Christodolov CS, et al. Interleukin 12 deficiency associated with recurrent infection. Proc Natl Acad Sci USA 1998; 95: 13125.
52. Rubins JB, Pomeroy C. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 1997; 65: 2975.
53. Kemp K, Bruunsgaard H, Skinhøj P, Pedersen BK. Pneumococcal infections in humans are associated with increased apoptosis and trafficking of type 1 cytokine-producing T cells. Infect Immun 2002; 70: 5019.
54. Matute-Bello G, Frevert CW, Liles WC, Nakamura M, Ruzinski JT, Ballman K, et al. Fas/Fas ligand system mediates epithelial injury, but not pulmonary host defenses, in response to inhaled bacteria. Infect Immun 2001; 69: 5768.
55. Torres JM, Cardenas O, Vasquez A, Schlossberg D. Streptococcus pneumoniae bacteremia in a community hospital. Chest 1998; 113: 387.
56. Ejstrud P, Kristensen B, Hansen JB, Madsen KM, Schonheyder HC, Sorensen HT. Risk and patterns of bacteraemia after splenectomy: a population-based study. Scand. J Infect Dis 2000; 32: 521.
57. Horgan KJ, Tanaka Y, Ginther-Luce GE, van Seventer GA, Nutman TB, Shaw S. CD45RB expression defines two interconvertable subsets of human CD4+ T cells with memory function. Eur J Immunol 1994; 24: 1240.
58. Amati L, Caradonna L, Magrone T, Mastronardi ML, Cuppone R, Cozzolongo R, et al. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin. Curr Pharm Des 2002; 8(11): 981-93.
59. Maesaki S. Drug delivery system of anti-fungal and parasitic agents. Curr Pharm Des 2002; 8(6): 433-40.
60. Xing Z. The hunt for new tuberculosis vaccines: anti-TB immunity and rational design of vaccines. Curr Pharm Des 2001; 7(11): 1015-37.